Correction to “Enhanced Clearance of HIV ‐1 Broadly Neutralizing Antibody VRC07 ‐523‐ LS During Viremia: Influences on Trial Design and Analysis”

Documenti analoghi

• Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis
  di: Atul Rawal, et al.
  Pubblicazione: (2025)
• Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics
  di: Hui Yu, et al.
  Pubblicazione: (2025)
• CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin
  di: Rubin Lubomirov, et al.
  Pubblicazione: (2025)
• Association of Protocol Design‐Related Factors With Enrollment Duration in Clinical Trials
  di: Hiroaki Tsuchiya, et al.
  Pubblicazione: (2026)
• Integrating Sustainability Pillars Into Trial Design Decision‐Making: Results of an International Survey
  di: Pritibha Singh, et al.
  Pubblicazione: (2025)